Related Experiment Videos
[T1G3 bladder tumors: 5 years later]
C Pegoraro1, C Bondovalli, B Dall'Oglio
1Divisione di Urologia, Azienda Ospedaliera Carlo Poma, Mantova.
Abstract:
We have evaluated 79 patients affected by bladder cancer T1G3: 31 underwent just endoscopy, 11 radiotherapy, 10 cystectomy and 27 topical chemotherapy. At five years 44 patients were alive and disease free, 7 were alive but recurrent in TA, 3 were alive but in metastatic progression, 17 were died because of the tumor, 3 died because of the therapy, and 5 died disease free. The authors believe that this patients could be treated with BCG as first treatment choice performing cystectomy when relapse or progression occuring.
Insights
For bladder cancer T1G3 patients, initial treatment with Bacillus Calmette-Guérin (BCG) may be more effective than endoscopy, radiotherapy, cystectomy, or topical chemotherapy, reserving cystectomy for relapses.
Area of Science:
- Urology
- Oncology
Background:
- Bladder cancer T1G3 represents a high-risk group requiring effective treatment strategies.
- Current treatment options for T1G3 bladder cancer include endoscopy, radiotherapy, cystectomy, and topical chemotherapy, with varying outcomes.
Purpose of the Study:
- To evaluate the long-term outcomes of different treatment modalities in patients with bladder cancer T1G3.
- To propose an optimized treatment pathway for T1G3 bladder cancer.
Main Methods:
- Retrospective analysis of 79 patients diagnosed with bladder cancer T1G3.
- Patients were treated with endoscopy, radiotherapy, cystectomy, or topical chemotherapy.
Main Results:
- At five years, 44 patients were disease-free, while others experienced recurrence, metastatic progression, or death from tumor or therapy.
- Significant variations in survival and recurrence rates were observed across different treatment groups.
Conclusions:
- The study suggests that Bacillus Calmette-Guérin (BCG) could be considered as a first-line treatment for T1G3 bladder cancer.
- Cystectomy may be reserved for cases with tumor relapse or progression after initial treatment.